Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT

Overall survival after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) using alemtuzumab, fludarabine, and melphalan is associated with high rates of mixed chimerism (MC) and secondary graft failure (GF). We hypothesized that peritransplantation alemtuzumab l...

Descripción completa

Detalles Bibliográficos
Autores principales: Geerlinks, Ashley V., Scull, Brooks, Krupski, Christa, Fleischmann, Ryan, Pulsipher, Michael A., Eapen, Mary, Connelly, James A., Bollard, Catherine M., Pai, Sung-Yun, Duncan, Christine N., Kean, Leslie S., Baker, K. Scott, Burroughs, Lauri M., Andolina, Jeffrey R., Shenoy, Shalini, Roehrs, Philip, Hanna, Rabi, Talano, Julie-An, Schultz, Kirk R., Stenger, Elizabeth O., Lin, Howard, Zoref-Lorenz, Adi, McClain, Kenneth L., Jordan, Michael B., Man, Tsz-Kwong, Allen, Carl E., Marsh, Rebecca A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368780/
https://www.ncbi.nlm.nih.gov/pubmed/37042921
http://dx.doi.org/10.1182/bloodadvances.2022009478

Ejemplares similares

Ejemplares similares